A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

To be considered for this study, most participants need to be at least 18 years old. However, for some parts of the study, younger individuals, aged 12 and above, might be able to take part if allowed in their country, provided they weigh at least 40 kg (about 6 stone 4 pounds). All participants need to be well enough to carry out most daily activities without too much difficulty.

For those with uveal melanoma that has spread, you might be eligible whether you've had previous treatments or not, as long as your cancer has progressed. If you have another type of melanoma (not uveal) that has spread, you would need to have tried all standard treatments or have no other good treatment options, and your cancer must have the specific GNAQ/11 genetic changes.

It's important that you are able and willing to have biopsies (taking small tissue samples) if the study requires them, though exceptions might be considered if a biopsy isn't medically possible for you.

If you decide to join this study, you will be taking a new medication called DYP688. The study involves regular visits to the clinic for assessments. These will include check-ups by doctors, blood tests, and scans to see how your body is responding to the treatment and whether the cancer is changing. You might also need to have biopsies collected to understand more about your cancer and how the drug is working. The exact number of visits and tests will be explained in detail by the study team, and it will depend on which part of the study you are in. You will take the medication for as long as it benefits you and you tolerate it well, with regular follow-up appointments after you stop taking the drug.